Publication Date
Spring 5-1-2025
School
School of Health Sciences
Major
Biology: Biomedical Sciences
Keywords
Schistosomiasis, praziquantel, resistance, efficacy, control, mass drug administration
Disciplines
Chemicals and Drugs | Community Health and Preventive Medicine | Medical Pathology | Medical Pharmacology | Medicinal and Pharmaceutical Chemistry | Other Medical Sciences | Public Health Education and Promotion
Recommended Citation
Eastham, Gabriela G., "A Review of Praziquantel Resistance in Schistosomes and the Future of Schistosomiasis Control" (2025). Senior Honors Theses. 1515.
https://digitalcommons.liberty.edu/honors/1515
Abstract
Schistosomiasis is a group of both acute and chronic parasitic trematode infections of the genus Schistosoma. Praziquantel (PZQ) has been the drug of choice to treat schistosomiasis for decades. Though it is effective against all three clinically relevant species, heavy reliance on PZQ has led to concerns of schistosome resistance, especially in areas that have implemented this drug in mass drug administration (MDA) programs. Although there is currently insufficient evidence to conclude that schistosomes are becoming resistant to PZQ on a large scale, other control methods are a necessity to best treat and eliminate schistosomiasis. This article summarizes the available literature concerning PZQ resistance in schistosomes, proposed mechanisms of resistance, genomic studies in schistosomes, and alternative methods of schistosomiasis control.
Included in
Chemicals and Drugs Commons, Community Health and Preventive Medicine Commons, Medical Pathology Commons, Medical Pharmacology Commons, Medicinal and Pharmaceutical Chemistry Commons, Other Medical Sciences Commons, Public Health Education and Promotion Commons
